If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands

Addiction

Volumn 105, Issue 6, 2010, Pages 1088-1097

  Vemer, Pepijn ^a   Rutten Van Mölken, Maureen P M H ^a   Kaper, Janneke ^b   Hoogenveen, Rudolf T ^c   Van Schayck, C P ^b   Feenstra, Talitha L ^c,d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chronic Disease Model; Cost effectiveness; Cost utility; Dynamic modelling; Reimbursement; Scenario analysis; Simulation model; The Netherlands; Tobacco control

Indexed keywords

AMFEBUTAMONE; DOPAMINE UPTAKE INHIBITOR; NICOTINE; NICOTINIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COUNSELING; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; MIDDLE AGED; NETHERLANDS; PSYCHOLOGICAL ASPECT; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; SMOKING; SMOKING CESSATION; STATISTICAL ANALYSIS; STATISTICS; TIME; TREATMENT OUTCOME; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BUPROPION; COST-BENEFIT ANALYSIS; COUNSELING; DATA INTERPRETATION, STATISTICAL; DOPAMINE UPTAKE INHIBITORS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NETHERLANDS; NICOTINE; NICOTINIC AGONISTS; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS; SMOKING; SMOKING CESSATION; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951989958     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.02901.x     Document Type: Article

References (39)

1. World Health Organization (WHO). WHO Framework Convention on Tobacco Control.
2. European Union Public Health Information System (EUPHIX). European Union Public Health Information System.
3. National Institute for Clinical Excellence (NICE). Brief Interventions and Referral for Smoking Cessation in Primary Care and Other Settings.
4. National Institute for Clinical Excellence (NICE). Smoking Cessation Services in Primary Care, Pharmacies, Local Authorities and Workplaces, Particularly for Manual Working Groups, Pregnant Women and Hard to Reach Communities.
5. Bertram M. Y., Lim S. S., Wallace A. L., Vos T. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia. Tob Control 2007 16 : 255 260.
6. Professional Assisted Cessation Therapy (PACT). Reimbursement for Smoking Cessation Therapy - A Healthcare Practitioner's Guide.
7. Nguyen-Kim L., Or Z., Paris V., Sermet C. The politics of drug reimbursement in England, France and Germany. 2005 99 : http://www.irdes.fr/ EspaceAnglais/Publications/IrdesPublications/QES099.pdf (accessed 9 April 2010).
8. van Volksgezondheid, Welzijn en Sport(VWS). Kiezen voor Gezond Leven 2007-2010 [Choosing a Healthy Life].
9. Kaper J., Wagena E. J., Severens J. L., Schayck C. P. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev 2005 1 : CD004305.
10. Reda A. A., Kaper J., Fikrelter H., Severens J. L., van Schayck C. P. Healthcare financing systems for increasing the use of tobacco dependence treatment [update]. Cochrane Database Syst Rev 2009 2 : CD004305.
11. Kroes M. E., Mastenbroek C. G. Stoppen-met-rokenprogramma: te verzekeren zorg! [Smoking Cessation Programs: Care to be Insured!]. Report number 290065312009. Diemen, the Netherlands: College van Zorgverzekeringen 2009.
12. Ministerie van Financiën. Dutch National Budget [Rijksbegroting], Art 41.
13. Kaper J., Wagena E. J., Willemsen M. C., van Schayck C. P. Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial. Addiction 2005 100 : 1012 1020. (Pubitemid 40897296)
14. Kaper J. Smoking Cessation Treatment and Its Reimbursement, the Costs and Effects.
15. Mulder I., van Genugten M. L. L., Hoogenveen R. T., de Hollander A. E. M., Bueno-de-Mesquita H. B. The impact of smoking on future pancreatic cancer: a computer simulation. Ann Oncol 1999 10 : 74 8. (Pubitemid 29333400)
16. Hoogenveen R. T., de Hollander A. E. M., van Genugten M. L. L. The chronic diseases modelling approach. Report number 266750001, May 1998. Bilthoven: RIVM. Available from http://www.rivm.nl/bibliotheek/rapporten/ 266750001.html (accessed 21 January 2010).
17. van den Berg B., Soethout J. E. Proefimplementatie 'Stoppen met roken'. Resultaat begeleidend onderzoek. [Pilot implementation Study 'Smoking Cessation': Results of accompanying research.]. Report number 1663, March 2009. Amsterdam: Regioplan. Available from http://www.regioplan.nl/media/pdf/id/513/ file-name/1663-Proefimplementatie+stoppen+met+roken (accessed21January2010).
18. Dutch Foundation on Smoking and Health (STIVORO). Roken, de harde feiten: Volwassenen 2003 [Smoking, the hard facts: Adults 2003].
19. Hoogenveen R. T., van Baal P. H., Boshuizen H. C., Feenstra T. L. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: the role of time since cessation. Cost Eff Resour Alloc 2008 6 : http://www.resource-allocation.com/content/6/1/1 (accessed 16 March 2010).
20. Feenstra T., Van Baal P., Hoogenveen R., Vijgen S., Stolk E., Bemelmans W. Cost-Effectiveness of Interventions to Reduce Tobacco Smoking in The Netherlands. An Application of the RIVM Chronic Disease Model. Report 260601003.
21. Lancaster T., Stead L. F. Individual behavioural counselling for smoking cessation [Review]. Cochrane Database Syst Rev 2008 3 : CD001292. DOI: 10.1002/14651858.CD001292.pub2.
22. Hoogendoorn M., Welsing P., Rutten-van Mölken M. P. M. H. Cost-effectiveness of varenicline compared with bupropion, NRT and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008 24 : 51 61. (Pubitemid 351160238)
23. Organization for Economic Cooperation and Development (OECD). OECD Statistics.
24. College voor Zorgverzekeringen. Richtlijnen Voor Farmaco-Economisch Onderzoek; Evaluatie En Actualisatie [Guidelines for pharmacoeconomic research: evaluation and actualization
25. Feenstra T. L., Hamberg-van Reenen H. H., Hoogenveen R. T., Rutten-van Mölken M. P. M. H. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005 8 : 178 190.
26. Hoogenveen R. T., van Baal P. H., Boshuizen H. C. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. Math Med Biol 2010 27 : 1 19.
27. Feenstra T. L., van Genugten M. L., Hoogenveen R. T., Wouters E. F., Rutten-van Mölken M. P. M. H. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001 164 : 590 596.
28. Struijs J. N., van Genugten M. L., Evers S. M., Ament A. J., Baan C. A., van den Bos G. A. Modeling the future burden of stroke in the Netherlands: impact of aging, smoking, and hypertension. Stroke 2005 36 : 1648 1655.
29. van Baal P. H., Feenstra T. L., Hoogenveen R. T., de Wit G. A., Brouwer W. B. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. Health Econ 2007 16 : 421 433.
30. van Baal P. H., Hoogenveen R. T., de Wit G. A., Boshuizen H. C. Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity. Popul Health Metrics 2006 4 : 14.
31. Dutch Foundation on Smoking and Health (STIVORO). Website: STIVORO for a Smoke Free Future.
32. van Baal P. H., Polder J. J., de Wit G. A., Hoogenveen R. T., Feenstra T. L., Boshuizen H. C. et al. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Med 2008 5 : e29.
33. Ronckers E. T., Groot W., Ament A. J. Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Med Decis Making 2005 25 : 437 448. (Pubitemid 41023171)
34. Fellows J. L., Bush T., McAfee T., Dickerson J. Cost effectiveness of the Oregon quitline 'free patch initiative'. Tob Control 2007 16 : i47 52.
35. Salize H. J., Merkel S., Reinhard I., Twardella D., Mann K., Brenner H. Cost-effective primary care-based strategies to improve smoking cessation: more value for money. Arch Intern Med 2009 169 : 230 236.
36. Joyce G. F., Niaura R., Maglione M., Mongoven J., Larson-Rotter C., Coan J. et al. The effectiveness of covering smoking cessation services for medicare beneficiaries. Health Serv Res 2008 43 : 2106 2123.
37. Bolin K., Mörk A., Willers S., Lindgren B. Varenicline as compared to bupropion in smokingcessation therapy - cost-utility results for Sweden. Respir Med 2008 102 : 699 710.
38. Casparie A., van Hout B. A., Simoons M. L. Guidelines and costs [in Dutch]. Ned Tijdschr Geneeskd 1998 142 : 2075 2077.
39. Kaper J., Wagena E. J., van Schayck C. P., Severens J. L. Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment. Pharmacoeconomics 2006 24 : 453 464. (Pubitemid 43765215)